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AP-1 = activator protein-1; DCs = dendritic cells; dsRNA = double-stranded RNA; GARG16 = glucocorticoid-attenuated response gene 16; IFN =
interferon; IKK = IκB kinase; IL-1R = interleukin-1 receptor; IP = interferon-inducible protein; IRAK = interleukin-1 receptor-associated kinase; IRF =
interferon regulatory factor; IRG-1 = immune response gene 1; LPS = lipopolysaccharide; LRR = leucine-rich repeats; MAL = MyD88-like adaptor;
MALP-2 = macrophage-activating lipopeptide-2; MAP = mitogen-activated protein; MyD88 = myeloid differentiation factor 88; NF-κB = nuclear
factor kappa B; RHIM = RIP homotypic interaction motif; RIP = receptor-interacting protein; TIR = Toll/interleukin-1 receptor; TLR = Toll-like receptor;
TRAF = TNF receptor associated factor; TRAM = TRIF-related adaptor molecule; TRIF = TIR-domain-containing adaptor-inducing interferon beta.
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Introduction
In Drosophila, Toll was initially identified as an essential
protein for the determination of dorsoventral polarity
during early embryogenesis. Subsequently, it was shown
that flies with a mutant Toll gene are highly susceptible to
fungal infection because of a defective production of
specific anti-fungi peptides upon infection, demonstrating
that Toll is a receptor that detects fungi invasion to trigger
immune responses [1]. In 1997, a human gene similar to
the  Toll gene was identified through the bioinformatic
approach [2]. Initial study demonstrated that this gene
product can promote the expression of genes encoding
inflammatory cytokines, suggesting that Toll in mammals
also has a function in innate immune responses. A further
five genes homologous to the Toll gene were
subsequently identified, and these genes were referred to
as the Toll-like receptor (TLR) family. So far, 11 members
of the TLR family (TLR1–TLR11) have been identified. In
both Drosophila and humans, Toll/TLRs consists of two
major domains characterized by leucine-rich repeats (LRR
domain) and Toll/interleukin-1 receptor (TIR domain)
domain (Fig. 1). The first evidence of TLRs in the
recognition of pathogens was reported from studies with
mice carrying a point-mutated or disrupted Tlr4 gene
[3,4]. These mice are unresponsive to bacterial
lipopolysaccharide (LPS), an integral component of the
outer membranes of Gram-negative bacteria that can
cause endotoxin shock. Subsequently, the generation of
knockout mice for each TLR gene has revealed respective
pathogens that can be recognized by each TLR. TLR2 is
involved in the responses to a variety of bacterial
components that include peptidoglycan, lipoproteins/
lipopeptides, glycosyl-phosphatidylinositol anchors from
Trypanosoma cruzi, and zymosan [5–7]. However,
recognition of these TLR2 ligands requires another TLR
family member. The mycoplasmal diacylated lipopeptide
MALP-2 is recognized by a heterodimer of TLR2 and
TLR6, whereas the bacterial triacylated lipopeptide
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Abstract
The family of Toll-like receptors (TLRs) senses conserved structures found in a broad range of
pathogens, causing innate immune responses that include the production of inflammatory cytokines,
chemokines and interferons. The signal transduction is initiated from the Toll/interleukin-1 receptor
(TIR) domain of TLRs after pathogen recognition. Almost all TLRs use a TIR-containing adapter MyD88
to activate a common signaling pathway that results in the activation of NF-κB to express cytokine
genes relevant to inflammation. Recently, three further TIR-containing adapters have been identified
and shown to selectively interact with several TLRs. In particular, activation of the TRIF-dependent
pathway confers antiviral responses by inducing anti-viral genes including that encoding interferon-β.
Taken together, these results indicate that the interaction between individual TLRs and the different
combinations of adapters directs appropriate responses against distinct pathogens.
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PAM3CSK4 is recognized by a heterodimer of TLR2 and
TLR1 [8,9]. Flagellin, a 55 kDa monomer obtained from
bacterial flagellum, the polymeric rod-like appendage
extending from the outer membrane of Gram-negative
bacteria, is also a potent pro-inflammatory inducer, which
is recognized by TLR5 [10]. TLR3 recognizes double-
stranded (ds) RNA that is generated in the lifecycle of
RNA viruses during infection [11]. TLR7 recognizes the
pharmaceutical compounds imiquimod (also known as
Aldara, R-837 or S-26308) and resiquimod (also known
as R-848 or S-28463) [12]. These compounds of the
imidazoquinoline family are known to have potent antiviral
and antitumor activities. TLR7 and its close relative TLR8
also recognize the single-stranded RNA present in
numerous viruses [13,14]. TLR9 recognizes unmethylated
2′-deoxyribo(cytidine-phosphate-guanosine) (CpG) DNA
motifs commonly present in bacterial and viral genomes
that have immunostimulatory activities [15]. It has recently
been shown that TLR11, which is abundant in the kidney
and bladder, senses uropathogenic bacteria [16] (Fig. 1).
Signal transduction pathway of interleukin-1
receptor (IL-1R) and TLRs
TLRs signal through a pathway conserved in the IL-1R
family [17]. The TIR domain, which is present in all TLRs
and IL-1R family members, is responsible for initiating a
signaling cascade through homophilic or heterophilic
interactions with TIR-domain-containing adapters. Almost
all TLRs and IL-1Rs recruit a TIR-domain-containing
adapter protein MyD88. Upon association with TLRs or IL-
1Rs, MyD88 in turn recruits members of IL-1R-associated
kinase (IRAK) family through interactions between the
death domains. Once phosphorylated, IRAK1 and IRAK4
dissociate from the receptor complex and then associate
with TRAF6, a member of the TRAF family. In contrast,
IRAK-M, which lacks the kinase activity, has been shown
to prevent dissociation of IRAK1 and IRAK4 from receptor
complex, thereby negatively regulating the TLR signaling
[18,19]. Activated TRAF6 can form a complex with the
ubiquitin-conjugating enzymes Ubc13 and Uev1A; TRAF6
then acts as the ubiquitin E3 ligase to activate the kinase
Figure 1
Structure and ligands for Toll-like receptors (TLRs). dsRNA, double-stranded RNA; LPS, lipopolysaccharide; TIR, Toll/interleukin-1 receptor.14
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TAK1, a member of the mitogen-activated protein (MAP)
kinase kinase kinase family [20,21]. TAK1 is thought to
activate two divergent pathways that lead to the
transcription factors NF-κB and AP-1 through kinase
cascades involving the canonical IκB kinase complex (IKK-
α, IKK-β, and IKK-γ) and MAP kinases (ERK, JNK, p38),
respectively, to induce the expression of target genes.
However, there is no evidence showing that TAK1 is really
involved in these pathways in vivo.
TIR-domain containing adapters
MyD88
MyD88 was originally identified as one of the myeloid
differentiation primary response genes rapidly induced by
IL-6 in M1 myeloleukemic cells. MyD88 contains two
domains characterized by a death domain and a TIR
domain, but lacks a putative transmembrane region,
suggesting that MyD88 might function as an adapter
protein in cytoplasm (Fig. 2). Consequently, MyD88 was
shown to be recruited to the IL-1R after IL-1 ligation and
to associate with IRAK1, resulting in the activation of
transcription factors NF-κB and AP-1 [22–24]. Studies on
MyD88-deficient mice clearly demonstrated that MyD88 is
an essential component in the responses to IL-1 and the
IL-1-related cytokine IL-18 [25]. All of the responses to IL-
1 and IL-18 and the activation of NF-κB and MAP kinases
were completely defective in cells from MyD88-deficient
mice. Subsequent investigation confirmed that MyD88 is
also used in TLR signaling. In MyD88-deficient mice, the
production of inflammatory cytokines such as tumor
necrosis factor-α, IL-1β and IL-6, the proliferation of B
cells, and the induction of endotoxin shock in response to
LPS (TLR4 ligand) are also completely abolished,
demonstrating that MyD88 is indispensable for the
responses to LPS in vivo [26]. In addition, cells from
MyD88-deficient mice are totally unresponsive to peptido-
glycan, lipoprotein, CpG DNA, and imidazoquinolines in
terms of cytokine production [12,27,28] (Fig. 3).
In addition to inflammatory responses mediated by the
MyD88-dependent pathway, a subset of TLRs can also
induce appropriate responses depending on the types of
pathogens. In TLR4-deficient macrophages, all of the
responses to LPS tested are completely abolished, and
the LPS-induced activation of NF-κB and MAP kinases
fails totally, indicating that TLR4 is an essential signaling
receptor for LPS [4,26]. In MyD88-deficient cells, the
production of inflammatory cytokines and the activation of
IRAK1 in response to LPS are also diminished. However,
NF-κB and MAP kinases are unexpectedly activated after
stimulation with LPS in MyD88-deficient cells, but the
activation was delayed in comparison with that in wild-type
cells [26]. In contrast, the activation of NF-κB and AP-1 in
response to other stimuli such as ligands of TLR2, TLR5,
TLR7, and TLR9 was completely defective in MyD88-
deficient cells. These aspects strongly suggest that one or
more alternative pathways leading to the expression of
certain genes associated with the delayed activation of
NF-κB and AP-1 probably exist in TLR4 signaling. In this
regard, genes induced by LPS in a MyD88-independent
manner were sought by subtractive screening, which
revealed that several genes were considerably induced
after stimulation with LPS in MyD88-deficient cells [29].
These include interferon-inducible protein (IP)-10, a
member of the CXC chemokines, glucocorticoid-
attenuated response gene 16 (GARG16) and immune-
responsive gene 1 (IRG-1), all of which are so-called IFN-
inducible genes. Northern blot analyses showed that
induction of these genes by LPS is comparable between
wild-type and MyD88-deficient macrophages, but is
completely abolished in TLR4-deficient cells. Thus, there
is a MyD88-independent pathway that mediates the
induction of IFN-inducible genes in TLR4 signaling [29].
The induction of some IFN-inducible genes is thought to
be regulated in part by the transcription factor IRF3, a
member of the interferon regulatory factor (IRF) family.
IRF3 is normally present in cytoplasm. Upon stimulation,
IRF3 is phosphorylated at multiple serine residues to form
a homodimer, moving to the nucleus, where it regulates
the expression of IFN-β or other target genes [30]. IRF3-
deficient mice are defective in the LPS-mediated induction
of IFN-β and IFN-inducible genes but are intact in the
production of inflammatory cytokines [31]. Furthermore,
the induction of some of IFN-inducible genes is regulated
in part secondarily to LPS-inducible IFN-β, which binds to
the IFN-α/β receptor and activates the classical
JAK–STAT pathway [32,33]. These results suggest that
IRF3 is responsible for the MyD88-independent induction
of IFN-inducible genes. Indeed, IRF3 is normally activated
in response to LPS in MyD88-deficient cells [29,34].
Thus, TLR4 is capable of inducing two different pathways,
namely the MyD88-dependent pathway responsible for
the induction of a core set of inflammatory cytokines and
the MyD88-independent pathway leading to the activation
Figure 2
Structure of Toll/interleukin-1 receptor (TIR)-containing adapter
proteins. DD, death domain.15
of IRF3 and IFN-β production (Fig. 3). In addition,
stimulation with LPS also augments the surface
expression of co-stimulatory molecules such as CD40,
CD80 and CD86 to induce the maturation of dendritic
cells (DCs) in MyD88-deficient mice, indicating that the
maturation of DCs also proceeds without the MyD88-
dependent pathway [35].
The MyD88-independent pathway is also used in TLR3
signaling. dsRNA (TLR3 ligand) also activates IRF3 and
induces the expression of IFN-inducible genes, and these
inductions are normal in MyD88-deficient cells [34].
Furthermore, the induction of IFN-inducible genes and the
activation of IRF3 are not observed after stimulation of
macrophages with TLR2 ligands, showing the specific use
of the MyD88-independent pathway in TLR3 and TLR4
signaling [29].
TIRAP (MAL)
The finding that a MyD88-independent pathway exists in
TLR4 signaling suggests that another protein, presumably
containing the TIR domain, acts downstream of TLR4 to
activate IRF3 independently of MyD88. In this model, a
second TIR-domain-containing adapter TIRAP (also
known as MAL) was identified by means of a database
search, on the basis of the similarity to the TIR domain
(Fig. 2) [36,37]. Expression of dominant-negative TIRAP,
which encodes only the TIR domain, blocked NF-κB
activation by TLR4 but not that by TLR9, and cell-
permeable peptide-mediated inhibition of TIRAP function
also decreased the induction of IP-10 by TLR4. Thus,
TIRAP was expected to participate specifically in the
TLR4-mediated MyD88-independent pathway. However,
TIRAP-deficient mice were unexpectedly impaired in the
activation of NF-κB and MAP kinases and in the
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Figure 3
Schematic representation of Toll-like receptor (TLR) signaling pathways. All TLRs except for TLR3 are thought to share the MyD88-dependent
pathway that activates NF-κB and mitogen-activated protein (MAP) kinases, leading to the induction of inflammatory cytokine genes. Interleukin-1
receptor-associated kinases (IRAKs) and TRAF6 are located downstream of MyD88. TIRAP is involved in the MyD88-dependent pathway
downstream of TLR2 and TLR4. TRIF is utilized in the TLR3-mediated and TLR4-mediated activation of interferon regulatory factor (IRF)3 and the
subsequent induction of IRF3-dependent gene expression such as interferon-β (IFN-β). TRAM is specifically involved in the activation of IRF3 in
TLR4 signaling. The complex of TBK1/IκB kinase-i (IKK-i) is responsible for the activation of IRF3 downstream of TRIF in TLR3 and TLR4 signaling.
TRAF6 is also involved in the TRIF-dependent activation of NF-κB and MAP kinases. Receptor-interacting protein (RIP) mediates TRIF-dependent
NF-κB activation. DD, death domain.16
production of inflammatory cytokines induced by TLR1,
TLR2, TLR6, and TLR4 ligands [38,39]. In contrast, the
TLR4-mediated maturation of DCs and the activation of
IRF3 were intact in TIRAP-deficient mice. Taken together,
these results indicate that TIRAP is unlikely to mediate the
MyD88-independent pathway; rather, it participates in the
MyD88-dependent pathway downstream of TLR2 and
TLR4 (Fig. 3).
TRIF (TICAM1)
A third TIR-domain containing the adapter TRIF (also
known as TICAM1) was independently identified by the
database search and as an interacting partner with TLR3
by yeast two-hybrid screening (Fig. 2) [40,41]. Initial
studies indicated that the overexpression of TRIF strongly
activates the IFN-β-dependent promoter, in contrast to
the lack of MyD88-mediated or TIRAP-mediated
activation of the IFN-β-dependent promoter. TRIF, as well
as MyD88 and TIRAP, also activates NF-κB after
overexpression. Moreover, the expression of dominant-
negative TRIF or the siRNA-mediated reduction of TRIF
expression blocked TLR3-dependent activation of IRF3.
These findings suggested that TRIF is involved in the
MyD88-independent pathway. Subsequent generations
of TRIF-deficient mice clearly revealed that they were
severely impaired in the induction of IFN-β and IFN-
inducible genes mediated by TLR3 and TLR4 ligands
[42]. Furthermore, activation of IRF3 was not observed in
TRIF-deficient cells. Analyses of mutant mice designated
lps2, which were generated by N-ethyl-N-nitrosourea-
induced random mutations, have also revealed that TRIF
is an lps2 gene product that is essential for responses
mediated by TLR3 and TLR4 [43]. Thus, TRIF is a critical
protein that mediates the MyD88-independent pathway in
TLR3 and TLR4 signaling (Fig. 3). Furthermore, it is
noteworthy that the production of inflammatory cytokines
induced by LPS was severely impaired in both TRIF-
deficient mice and MyD88-deficient mice. However, LPS-
induced activation of IRAK1 and early-phase activation of
NF-κB and MAP kinases was normally found in TRIF-
deficient cells; this is in contrast to MyD88-deficient cells,
which show impaired activation of IRAK1 and late-phase
activation of NF-κB and MAP kinases [29,42]. These
findings strongly suggest that both the MyD88-
dependent and MyD88-independent pathways are
required for the induction of genes for inflammatory
cyokines, whereas activation of the MyD88-independent
(TRIF-dependent) pathway is sufficient to induce IRF3-
dependent IFN-β and IFN-inducible genes. In contrast,
activation of the MyD88-dependent pathway is sufficient
for the induction of inflammatory cytokines in the case of
TLR2, TLR5, TLR7, TLR9, and IL-1R. Thus, only TLR4
uses both the MyD88-dependent and MyD88-
independent pathways for the induction of inflammatory
cytokines, although it remains unclear why both pathways
are necessary.
Downstream events of TRIF-dependent activation of NF-
κB are still unclear. It has recently been reported that TRIF
associates directly with TRAF6 [44]. Three TRAF-binding
motifs are present in the amino-terminal region of TRIF,
and a mutagenesis study demonstrated that these motifs
are necessary for association with TRAF6. Disruption of
TRAF-binding motifs in TRIF resulted in reduced activation
of NF-κB. Given that TRAF6 activates NF-κB but not the
IFN-β promoter, TRIF activates NF-κB by recruitment of
TRAF6 via the TRAF-binding motifs [44]. In addition to
amino-terminal TRAF-binding motifs, NF-κB is also
activated from the carboxy-terminal domain of TRIF, which
lacks the TIR domain [40]. It has recently been reported
that the kinases receptor-interacting protein (RIP)-1 and
RIP3 are recruited to TRIF through the RIP homotypic
interaction motif (RHIM) found in the carboxy-terminal
region of TRIF [45]. In cells deficient for the Rip1 gene,
TLR3-mediated activation of NF-κB was selectively
impaired, whereas activation of JNK or IFN-β promoter
was intact, indicating that TLR3 uses RIP1 for activation of
NF-κB downstream of TRIF; this was in contrast to other
TLRs, which use IRAKs for the activation of NF-κB (Fig. 3).
TRAM (TICAM2, TIRP)
The fourth TIR-domain-containing adapter was
independently identified in the database search and termed
TRAM, TIRP, or TICAM2 (Fig. 2) [41,46,47]. It has recently
been demonstrated that responses of TRAM-deficient mice
to TLR2, TLR7, and TLR9 ligands are intact in terms of
production of inflammatory cytokines [48]. However, the
LPS (TLR4 ligand)-induced production of inflammatory
cytokines was specifically impaired in TRAM-deficient
mice. Moreover, the induction of IFN-β and activation of
IRF3 in response to LPS was severely impaired in TRAM-
deficient mice, indicating that TRAM is also involved in the
MyD88-independent pathway. These responses in TRAM-
deficient mice are very similar to those found in TRIF-
deficient mice, except for TLR3, to which TRAM-deficient
mice are normally responsive. Thus, TRAM specifically
mediates the MyD88-independent pathway in TLR4
signaling but not in TLR3 signaling (Fig. 3).
Non-canonical IKKs
The canonical IKKs (IKK-α and IKK-β) are required for the
activation of NF-κB mediated by TLRs and IL-1R [17].
These IKKs phosphorylate NF-κB inhibitor IκBs, leading to
the ubiquitination and degradation of IκBs by the
proteasome pathway. NF-κB in turn translocates into the
nucleus, where it induces the expression of target genes.
Two kinases related to the canonical IKKs, TBK1 (also
known as NAK and T2K) and IKK-i (also known as IKK-ε),
were identified [49,50]. These ‘non-canonical’ IKKs were
also implicated in NF-κB activation, although the precise
mechanism is unclear. It has recently been shown that
forced expression of either TBK1 or IKK-i strongly
enhances IFN-β-promoter-dependent reporter gene
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expression [51,52]. Furthermore, the kinase activities are
required for IFN-β-promoter activation, suggesting that
TBK1/IKK-i activates IFN-β promoter by phosphorylating
one or more appropriate substrates. Indeed, TBK1/IKK-i is
shown to be capable of phosphorylating the serine
residues that are critical for activating IRF3 in vitro
[51,52]. In cells deficient for the Tbk1 gene, the dsRNA-
mediated or LPS-mediated activation of IRF3 (dimer
formation, nuclear localization) and induction of IRF3-
dependent genes such as IFN-β, GARG16 and IP-10
were considerably reduced, whereas the induction of
inflammatory cytokines, which is regulated by the MyD88-
dependent pathway and activation of NF-κB and MAP
kinases, was not impaired [53]. Thus, TBK1 is specifically
involved in the induction of IRF3-dependent genes
mediated by TLR3 and TLR4 (Fig. 3). In contrast, IKK-i-
deficient cells normally respond to LPS and dsRNA to
induce both IRF3-dependent and NF-κB-dependent gene
expression. However, in TBK1/IKK-i doubly deficient cells
the residual induction of IFN-inducible genes found in
TBK1-deficient cells was completely abolished, indicating
that IKK-i also participates in the pathway dependent on
TLR3 and TLR4 [54]. It has recently been reported that
TRIF also binds TBK1 through the amino-terminal region
which shares the binding with TRAF6, and the association
between TRIF and TBK1 seems to require the kinase
activity of TBK1 [44]. Furthermore, expression of the
kinase-negative mutant of TBK1 significantly blocked
TRIF-dependent activation of the IFN-β promoter, thus
indicating that TBK1 and IKK-i act downstream of TRIF.
TBK1 and IKK-i also bind TANK (also known as I-TRAF)
and a newly identified TANK-related protein NAP1
[49,55,56]. Thus, it is speculated that TBK1 is recruited to
the TRIF complex to become activated, then forms a
signaling complex containing IKK-i, TANK, and perhaps
NAP1, to phosphorylate IRF3.
Conclusions and remarks
The discovery of a series of TIR-containing adapters
revealed that there are differences in the signal
transduction pathways of individual TLRs, which might
induce different effector responses that are specific to
each TLR, as well as redundant responses that are
conserved in all TLRs. One of the effector’s functions is to
produce IFN-β, which is mediated by a TRIF-dependent
pathway in TLR3 and TLR4 signaling, thus implying roles of
TLRs for the detection of virus infection and the induction
of appropriate anti-viral responses. In addition, TLR7,
TLR8, and TLR9 are also implicated in the recognition of
viral products. Indeed, TLR7 and TLR9 ligands are known
to have abilities to produce IFNs as well as inflammatory
cytokines from a certain subset of DCs. Interestingly,
responses to both TLR7 and TLR9 ligands are entirely
dependent on MyD88 [57]. Thus, TLR7 and TLR9 seem to
have one or more unique signaling pathways that produce
IFNs. Given that TLR7 and TLR9 are structurally related,
these TLRs probably share the same signaling pathway.
Although there is still a need to characterize a specific
pathway that each TLR uses, understanding such
pathways will be therapeutically useful in the control of
inflammatory and anti-viral responses.
Roles of TLRs in the pathogenesis of rheumatoid arthritis
have been investigated. It was demonstrated that
peptidoglycan and bacterial DNA, which is recognized by
TLR2 and TLR9, could be detected in the synovium of
patients with rheumatoid arthritis [58]. Furthermore,
synovial cells express low levels of TLR2 and TLR9, and
TLR2 is upregulated by exposure to peptidoglycan [59,60].
In addition, TLRs have been shown to recognize
endogenous ligands present in tissues and cells in the
absence of bacterial infection. TLR2 activates cells through
the recognition of heat shock protein 70 and necrotic cells,
both of which are detected in synovial tissue of patients
with rheumatoid arthritis [61]. These findings suggest that
TLRs contribute to the pathogenesis of rheumatoid
arthritis, and targeting the TLR signaling pathway will raise
the possibility of a drug discovery to control inflammation
induced in patients with rheumatoid arthritis.
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